Fractyl Health
Fractyl Health (NASDAQ: GUTS) is a clinical-stage metabolic therapeutics company developing novel organ-editing therapies for obesity and type 2 diabetes. The company's lead program, Revita, is a duodenal mucosal resurfacing (DMR) device delivered via an outpatient endoscopic procedure designed to remodel the duodenal lining and address abnormal nutrient sensing and signaling. Revita is being studied in the REMAIN-1 pivotal trial as a weight maintenance therapy for patients who discontinue GLP-1 medications. Fractyl is also advancing Rejuva, an AAV-based pancreatic gene therapy platform led by RJVA-001, designed to restore endogenous insulin production for patients with type 2 diabetes. Revita has received CE mark in Europe and NUB reimbursement authorization in Germany; in the U.S. it is investigational. The company was founded in 2010 by Harith Rajagopalan and Jay Caplan and is headquartered in Burlington, Massachusetts. Fractyl completed its IPO on the Nasdaq Global Market in February 2024 under ticker GUTS.
Public Company
Fractyl Health is publicly traded
IPO'd on Feb 2, 2024
This company is no longer available on our private secondary market. Shares can be traded publicly under GUTS.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2010
Employees
100–120
Total Funding
$366M
9 rounds
Secondary Signals (Note: SetterVC does not verify the accuracy of these)
1 signalPriced $20M underwritten public offering at $1.05/share plus warrants, well below the $15 Feb-2024 IPO price
Steep post-IPO price markdown signals valuation compression and dilution risk
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $366M across 9 rounds
Last updated 09-26-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Feb 2, 2024 | IPO Press release | $110M gross proceeds | — | |
| Sep 7, 2023 | Venture Debt | $30M | — | Symbiotic Capital Opportunities Holding, L.P., Catalio Structured Opportunities AIV I LP |
| Jan 11, 2022 | Convertible Notes | $20.1M | — | Not disclosed |
Leadership
Harith Rajagopalan
Co-Founder & Chief Executive Officer
Jay Caplan
Co-Founder
Lara Smith Weber
Chief Financial Officer
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Novo Nordisk
Danish pharmaceutical giant and dominant GLP-1 incumbent (Ozempic, Wegovy) for type 2 diabetes and obesity; primary pharmacologic competitor to Fractyl's metabolic disease focus.
Eli Lilly
Maker of GLP-1/GIP agonists Mounjaro and Zepbound for diabetes and obesity; key competitor in the metabolic disease pharmacotherapy market.
Pfizer
Large-cap pharmaceutical company building a pipeline of oral GLP-1 and metabolic disease candidates competing in the obesity/T2D space.
Structure Therapeutics
Clinical-stage biotech developing oral small-molecule GLP-1 receptor agonists for obesity and metabolic disease.
Altimmune
Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and MASH.
Endogenex
Private medtech developing a pulsed electric field endoscopic procedure (ReCET) targeting duodenal remodeling for type 2 diabetes, directly analogous to Fractyl's DMR approach.
Fractyl Health Investment FAQ
Fractyl Health FAQ
Yes, Fractyl Health is publicly traded under the ticker symbol GUTS on the NASDAQ. The company went public in Feb 2, 2024.
Fractyl Health trades under the ticker symbol GUTS on the NASDAQ. It began trading in Feb 2, 2024.
Fractyl Health (GUTS on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker GUTS to place an order.
Fractyl Health went public in Feb 2, 2024 via ipo. Fractyl Health has traded on the Nasdaq Global Market as GUTS since its IPO on February 2, 2024, which priced 7,333,333 shares at $15.00 per share for gross proceeds of approximately $110 million, with BofA Securities, Morgan Stanley and Evercore ISI as joint book-running managers. The shares have since fallen below $1.00, and on September 10, 2026 Nasdaq notified the company that its securities are subject to delisting because it did not regain compliance with the $1.00 minimum bid price requirement within the 180-day grace period that ended September 9, 2026. Fractyl said it would request a hearing before a Nasdaq Hearings Panel, which automatically stays any suspension or delisting while the process runs, and its stockholders approved a reverse stock split at a ratio of between 1-for-5 and 1-for-15 on September 24, 2026 to help restore compliance.
Fractyl Health raised $366M across 9 disclosed funding rounds prior to its public listing.
Fractyl Health was co-founded by Harith Rajagopalan, and Jay Caplan in 2010.
Fractyl Health is headquartered in Burlington, MA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.